Overview

Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)

Status:
Terminated
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a single dose of IL-10 compared to placebo is safe and effective in reducing the incidence of post-ERCP acute pancreatitis for subjects with increased risk.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.